<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2106233833
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Skyrizi 600 mg per 10 ml 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RISANKIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11103.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AbbVie Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AbbVie Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AbbVie Inc
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Skyrizi contains the active substance risankizumab</p><p>&nbsp;</p><p>Skyrizi is used to treat adult patients with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moderate to severe Crohn&rsquo;s disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moderate to severe ulcerative colitis</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Skyrizi</strong></p><p>&nbsp;</p><p><strong>Do not use SKYRIZI if you are</strong> allergic to risankizumab or any of the ingredients in SKYRIZI.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious allergic reactions</strong>. Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, dizziness, feeling lightheaded (low blood pressure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your face, eyelids, lips, mouth, tongue, or throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing or throat tightness &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest tightness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections and Tuberculosis.</strong> SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB.</p><p>&nbsp;</p><p>Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, sweats, or chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in your mucus (phlegm) &nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle aches</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warm, red, or painful skin or sores on your body different from your psoriasis &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea or stomach pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burning when you urinate or urinating more often than normal</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>It is not known if SKYRIZI is safe and effective in children under 18 years of age</p><p>&nbsp;</p><p><strong>Other medicines and Skyrizi</strong></p><p><strong>&nbsp;</strong></p><p><strong>Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.</p><p><strong>Tell your healthcare provider about all the medicines you take,</strong> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p>&nbsp;</p><p><strong>Pregnancy, contraception and breast-feeding</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. It is not known if SKYRIZI can harm your unborn baby Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment.</p><p>&nbsp;</p><p>If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine. It is not known if SKYRIZI passes into your breast milk.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Skyrizi is not likely to affect your driving and use of machines.</p><p>&nbsp;</p><p><strong>Skyrizi contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Starting doses</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="4"><p><strong>Crohn&rsquo;s disease</strong></p></td><td style="vertical-align:top"><p><strong>How much?</strong></p></td><td style="vertical-align:top"><p><strong>When?</strong></p></td></tr><tr><td style="vertical-align:top"><p>600&nbsp;mg</p></td><td style="vertical-align:top"><p>When your doctor tells you</p></td></tr><tr><td style="vertical-align:top"><p>600&nbsp;mg</p></td><td style="vertical-align:top"><p>4 weeks after 1<sup>st</sup> dose</p></td></tr><tr><td style="vertical-align:top"><p>600&nbsp;mg</p></td><td style="vertical-align:top"><p>4 weeks after 2<sup>nd</sup> dose</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="4"><p><strong>Ulcerative colitis</strong></p></td><td style="vertical-align:top"><p><strong>How much?</strong></p></td><td style="vertical-align:top"><p><strong>When?</strong></p></td></tr><tr><td style="vertical-align:top"><p>1&nbsp;200&nbsp;mg</p></td><td style="vertical-align:top"><p>When your doctor tells you</p></td></tr><tr><td style="vertical-align:top"><p>1&nbsp;200&nbsp;mg</p></td><td style="vertical-align:top"><p>4 weeks after 1<sup>st</sup> dose</p></td></tr><tr><td style="vertical-align:top"><p>1&nbsp;200&nbsp;mg</p></td><td style="vertical-align:top"><p>4 weeks after 2<sup>nd</sup> dose</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Maintenance doses</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:94%"><tbody><tr><td rowspan="3"><p><strong>Crohn&rsquo;s disease</strong></p></td><td colspan="2"><p><strong>How much?</strong></p></td><td><p><strong>When?</strong></p></td></tr><tr><td style="vertical-align:top"><p>1<sup>st</sup> maintenance dose</p></td><td style="vertical-align:top"><p>&nbsp;360&nbsp;mg</p></td><td><p>4 weeks after the last starting dose (at&nbsp;week 12)</p></td></tr><tr><td style="vertical-align:top"><p>Further doses</p></td><td style="vertical-align:top"><p>360&nbsp;mg</p></td><td><p>Every 8 weeks, starting after the 1<sup>st</sup> maintenance dose</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:94%"><tbody><tr><td rowspan="3"><p><strong>Ulcerative colitis</strong></p></td><td colspan="2"><p><strong>How much?</strong></p></td><td><p><strong>When?</strong></p></td></tr><tr><td style="vertical-align:top"><p>1<sup>st</sup> maintenance dose</p></td><td style="vertical-align:top"><p>180&nbsp;mg or 360&nbsp;mg</p></td><td><p>4 weeks after the last starting dose (at&nbsp;week 12)</p></td></tr><tr><td style="vertical-align:top"><p>Further doses</p></td><td style="vertical-align:top"><p>180&nbsp;mg or 360&nbsp;mg</p></td><td><p>Every 8 weeks, starting after the 1<sup>st</sup> maintenance dose</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Adults with Crohn&rsquo;s disease or ulcerative colitis will receive their starter doses with SKYRIZI through a vein in the arm (intravenous infusion) in a healthcare facility by a healthcare provider. After completing the starter doses, patients will receive SKYRIZI as 1 or more injections under the skin (subcutaneous injection) using the prefilled cartridge with on-body injector.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you use more Skyrizi than you should</strong>.&nbsp;</p><p>If you inject more SKYRIZI than prescribed, call your healthcare provider right away.</p><p>&nbsp;</p><p><strong>If you forget to use Skyrizi</strong></p><p>If you miss your SKYRIZI dose, inject a dose as soon as you remember. Then, take your next dose at your regular scheduled time. Call your healthcare provider if you are not sure what to do.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you stop using Skyrizi</strong></p><p>Do not stop using Skyrizi without talking to your doctor first. If you stop treatment, your symptoms may come back.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Serious side effects</strong></p><p>SKYRIZI may cause serious side effects. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, sweats, or chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in your mucus (phlegm) &nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle aches</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warm, red, or painful skin or sores on your body different from your psoriasis &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea or stomach pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burning when you urinate or urinating more often than normal</p><p>&nbsp;</p><p><strong>Liver problems may happen while being treated for Crohn&rsquo;s disease or ulcerative colitis.</strong>&nbsp; A person with Crohn&rsquo;s disease who received SKYRIZI by intravenous infusion (through a vein in the arm) developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and up to 12 weeks of treatment with SKYRIZI. Your healthcare provider may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unexplained rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin and eyes (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach (abdominal pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dark urine</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects</strong></p><p>Tell your doctor, pharmacist or nurse if you get any of the following side effects</p><p>&nbsp;</p><p>The most common side effects of SKYRIZI in people treated for Crohn&rsquo;s disease and ulcerative colitis include:</p><p>&nbsp;</p><p><strong>Very common:</strong> may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory infections</p><p>&nbsp;</p><p><strong>Common:</strong> may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint Pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reactions (such as redness or pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach (abdominal) pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cells (anemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the vial label and outer carton after &lsquo;EXP&rsquo;.</p><p>Store in a refrigerator at 2&deg;C to 8&deg;C.</p><p>Do not freeze.</p><p>Do not shake.</p><p>Keep in the original cartons to protect from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Skyrizi contains</strong></p><p><strong><u>SKYRIZI 600 mg/10 mL (60 mg/mL) in vial for infusion</u></strong></p><p><strong>Active ingredient:</strong> risankizumab</p><p><strong>inactive ingredients:</strong> glacial acetic acid, polysorbate 20, sodium acetate, trehalose, and Water for Injection, USP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                SKYRIZI (risankizumab ) 600 mg/10 mL (60 mg/mL) vial contains a sterile and preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution. Each glass vial is closed with a stopper and blue flip cap.
	
Each pack contains 1 vial 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Bulk Manufacturer:&nbsp;</strong></p><p>Patheon Italia S.P.A, Viale Gian Battista Stucchi 110, Monza, 20900, Italy<strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder:&nbsp;</strong></p><p>AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA</p><p><strong>Batch Releaser:</strong></p><p>AbbVie S.r.l., S.R. 148 Pontina, km 52 SNC, Campoverde di Aprilia (LT), 04011, Italy</p><p><br />&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in June 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي سكاي ريزي على المادة الفعالة ريسانكيزوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستعمل سكاي ريزي لعلاج البالغين الذين يعانون من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض كرون <strong>المتوسط إلى الشديد</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون التقرحي <strong>المتوسط إلى الشديد</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل سكاي ريزي</strong></p><p>&nbsp;</p><p dir="RTL"><strong>لا تستعمل سكاي ريزي إذا كنت تعاني </strong>من حساسية تجاه ريسانكيزوماب أو إي من مكونات سكاي ريزي.<strong> </strong>(المذكورة في القسم ٦).</p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تفاعلات تحسسية شديدة.</strong> توقف عن استعمال سكاي ريزي واطلب عناية طبية إسعافية على الفور إذا أصبت بأي من الأعراض التالية للتفاعلات التحسسية الشديدة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء، دوار، دوخة خفيفة (انخفاض ضغط الدم)&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه، الجفون، الفم، اللسان، أو الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس أو ضيق الحنجرة &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، شرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالات عدوى التهابات أو السل.</strong> قد يقلل سكاي ريزي من قدرة جهازك المناعي على محاربة حالات العدوى وقد يزيد من إمكانية إصابتك بالعدوى. يجب أن يفحصك مزوّد الرعاية الصحية الخاص بك بحثا عن حالات العدوى والسلّ قبل بدء العلاج بـ سكاي ريزي وقد يعالج إصابتك بالسلّ قبل أن تبدأ العلاج بـ سكاي ريزي إذا كانت لديك إصابة سابقة بالسلّ أو إذا كنت مصابا بالسلّ النشط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يراقبك مزوّد الرعاية الصحية عن كثب بحثا عن علامات وأعراض السلّ في أثناء علاجك بـ سكاي ريزي وبعده. أخبر مزوّد الرعاية الصحية الخاص بك على الفور إذا كنت مصابا بعدوى أو إذا كانت لديك أعراض للعدوى، وهي تشمل:&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة، تعرّق، أو قشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في الإفراز المخاطي (القشع) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام عضلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلد دافئ، أحمر أو مؤلم أو تقرحات على جسمك تختلف عن إصابتك بالصدفية &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال أو ألم المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة عند التبوّل أو زيادة عدد مرات التبول عن المعتاد</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">من غير المعروف ما إذا كان سكاي ريزي آمنا وفعالا عند الأطفال الأصغر من ١٨ عاما.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى و سكاي ريزي </strong></p><p dir="RTL"><strong>قبل أن تبدأ باستعمال سكاي ريزي، أخبر طبيبك عن كل حالاتك الصحية، وهذا يشمل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت قد تلقيت مؤخراً أو على وشك أن تتلقى لقاحاً. الأدوية التي تتداخل مع عمل الجهاز المناعي قد تزيد من إمكانية إصابتك بالعدوى &nbsp;&nbsp;&nbsp;&nbsp;بعد تلقي اللقاحات الحيّة. يجب أن تتجنب تلقّي لقاحات حيّة قبل بدء العلاج بـ سكاي ريزي مباشرة، أو في أثنائه أو بعده مباشرة. أخبر مزوّد الرعاية الصحية الخاص بك أنك تتناول سكاي ريزي قبل تلقّي أي لقاح.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر مزوّد الرعاية الصحية الخاص بك عن كافة الأدوية التي تتناولها،</strong> وهذا يشمل الأدوية الموصوفة وتلك التي يمكن الحصول عليها دون وصفة طبية، الفيتامينات، والمكمّلات العشبية.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل، منع الحمل والإرضاع</strong></p><p dir="RTL">إذا كنت حاملا، أو تعتقدين بأنك حامل أو تخططين للإنجاب، فاطلبي نصيحة طبيبك قبل استعمال هذا الدواء. من غير المعروف ما إذا كان سكاي ريزي يمكن أن يؤذي طفلك الذي لم يولد بعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت امرأة يمكنها الحمل، فيجب أن تستعملي وسيلة لمنع الحمل أثناء استعمالك لهذا الدواء لمدة ٢١ أسبوعا على الأقل بعد آخر جرعة تتلقينها من سكاي ريزي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدّثي إلى طبيبك إن كنت مرضعا أو إن كنت تخططين للإرضاع قبل استعمال هذا الدواء. من غير المعروف ما إذا كان سكاي ريزي ينتقل إلى حليب الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستعمال الآلات</strong></p><p dir="RTL">من غير المرجّح أن يؤثر سكاي ريزي على قدرتك على القيادة أو استعمال الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي سكاي ريزي على الصوديوم</strong></p><p dir="RTL">هذا الدواء يحتوي على أقل من ١ ميلي مول من الصوديوم (٢٣ ملغ) في كل خرطوشة، أي يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دوما على استعمال هذا الدواء ملتزما تماما بالطريقة التي وصفها لك طبيبك أو الصيدلاني. اسأل طبيبك أو الصيدلاني إذا لم تكن متأكدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الأولية:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="4" style="vertical-align:top"><p dir="RTL">مرض كرون</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة</p></td><td style="vertical-align:top"><p dir="RTL">وقت الجرعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">600 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">عندما يخبرك طبيبك</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">600 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">بعد 4 أسابيع من الجرعة الأولى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">600 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">بعد 4 أسابيع من الجرعة الثانية</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="4" style="vertical-align:top"><p dir="RTL">التهاب القولون التقرحي</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة</p></td><td style="vertical-align:top"><p dir="RTL">وقت الجرعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">1200 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">عندما يخبرك طبيبك</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">1200 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">بعد 4 أسابيع من الجرعة الأولى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">1200 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">بعد 4 أسابيع من الجرعة الثانية</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">العلاج طويل الأمد:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p dir="RTL">مرض كرون</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">الجرعة</p></td><td style="vertical-align:top"><p dir="RTL">وقت الجرعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعة الأولى في العلاج طويل الأمد</p></td><td style="vertical-align:top"><p dir="RTL">360 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">بعد 4 أسابيع من آخر جرعة أولية (12 اسبوعًا&nbsp; من بدء العلاج)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعات اللاحقة</p></td><td style="vertical-align:top"><p dir="RTL">360 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">كل 8 أسابيع، من أول جرعة في العلاج طويل الأمد</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p dir="RTL">التهاب القولون التقرحي</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">الجرعة</p></td><td style="vertical-align:top"><p dir="RTL">وقت الجرعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعة الأولى في العلاج طويل الأمد</p></td><td style="vertical-align:top"><p dir="RTL">180ملغ أو 360 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">بعد 4 أسابيع من آخر جرعة أولية (12 اسبوعًا&nbsp; من بدء العلاج)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعات اللاحقة</p></td><td style="vertical-align:top"><p dir="RTL">180ملغ أو 360 ملغ</p></td><td style="vertical-align:top"><p dir="RTL">كل 8 أسابيع، من أول جرعة في العلاج طويل الأمد</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتلقى المرضى البالغين المصابين بداء كرون أو التهاب القولون التقرحي العلاج مع سكاي ريزي بجرعة ابتدائية من خلال الحقن الوريدي في الذراع (التسريب في الوريد)في منشأة رعاية صحية من قبل مقدم رعاية صحية. بعد الانتهاء من الجرعات الابتدائية سيتلقى المريض العلاج مرة أو أكثر عن طريق حقنة تحت الجلد (حقن تحت الجلد) باستخدام خرطوشة مملوءة مسبقا مع حاقن على الجسم.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>إذا استعملت كمية أكثر مما ينبغي من سكاي ريزي</strong></p><p dir="RTL">إذا حقنت كمية أكثر مما وصف لك من سكاي ريزي، فاتصل بمزوّد الرعاية الصحية الخاص بك على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تستعمل سكاي ريزي</strong></p><p dir="RTL">إذا نسيت إحدى جرعات سكاي ريزي، فاحقنها حالما تتذكر. ثم خذ جرعتك التالية في وقتها النظامي حسب البرنامج. اتصل بمزوّد الرعاية الصحية الخاص بك إن لم تكن متأكدا مما يجب أن تفعله.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استعمال سكاي ريزي</strong></p><p dir="RTL">لا تتوقف عن استعمال سكاي ريزي دون التحدث إلى طبيبك أولا. إذا أوقفت العلاج، قد تعود أعراضك للظهور من جديد.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بخصوص استعمال هذا الدواء، فاسأل طبيبك، الصيدلاني أو الممرضة.&nbsp;&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب هذا الدواء تأثيرات جانبية، رغم أنها لا تصيب كافة الأشخاص.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التأثيرات الجانبية الخطيرة</strong></p><p dir="RTL">قد يسبب سكاي ريزي تأثيرات جانبية خطيرة. أخبر مزوّد الرعاية الصحية الخاص بك على الفور إذا كنت مصابا بعدوى أو إذا كانت لديك أعراض للعدوى، وهي تشمل:&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة، تعرق، أو قشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في الإفراز المخاطي (القشع) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام عضلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلد دافئ، أحمر أو مؤلم أو تقرحات على جسمك تختلف عن إصابتك بالصدفية &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال أو ألم المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة عند التبوّل أو زيادة عدد مرات التبول عن المعتاد</p><p dir="RTL">&nbsp;</p><p>مشاكل في الكبد: قد يعاني منها الأشخاص المصابون بداء كرون أو التهاب القولون التقرحي. قد يعاني مريض كرون أو التهاب القولون التقرحي والذي يتلقى سكايريزي بتغييرات في اختبارات الدم الخاصة بوظائف الكبد والتي قد تتطلب دخول المستشفى. سيقوم مقدم الرعاية الصحية الخاص بك بإجراء فحوصات الدم لفحص الكبد قبل وأثناء و حتى 12 أسبوعا على الأقل من العلاج باستخدام سكاي ريزي. قد يوقف مقدم الرعاية الصحية الغلاج باستخدام سكايريزي إذا كنت تعاني من مشاكل في الكبد. أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا لاحظت أيا من الأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; طفح جلدي غير مفسر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التعب (التعب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعينين (اليرقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المعدة (آلام البطن)&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; البول الداكن</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى&nbsp; </strong></p><p dir="RTL">أخبر طبيبك، الصيدلاني أو الممرضة إذا أصبت بأي من التأثيرات الجانبية التالية:</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدا:</strong> قد تصيب أكثر من ١ من ١٠ أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى في القسم العلوي من الجهاز التنفسي</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة:</strong> قد تصيب حتى ١ من ١٠ أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع الحقن (كالاحمرار أو الألم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المعدة (آلام في البطن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إحتفظ بهذا الدواء بعيدا عن مرأى الأطفال ومتناول أيديهم.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المبيّن على لصاقة الخرطوشة وعلى الكرتونة الخارجية بعد EXP. &nbsp;</p><p dir="RTL">احفظه في الثلاجة ضمن حرارة تتراوح بين ٢ - ٨ درجة مئوية.</p><p dir="RTL">لا تجمده.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">لا تهزّه.</p><p dir="RTL">احتفظ به في عبوته الكرتونية الأصلية لتحميه من الضوء.</p><p dir="RTL">لا تتخلص من الأدوية في مياه المجاري العامة أو مع نفايات المنزل. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي مكونات سكاي ريزي</strong></p><p dir="RTL">سكاي ريزي <strong>٦٠٠ ملغ/١٠ مل (٦٠ ملغ/١ مل</strong><strong>(</strong><strong> في قناني للتسريب</strong><strong>/</strong><strong>للحقن</strong><strong>.</strong></p><p dir="RTL"><strong>المادة الفعالة</strong>: ريسانكيزوماب</p><p dir="RTL"><strong>المكونات غير الفعالة</strong>: حمض الخلّ، بولي سوربات ٢٠، ثلاثي هيدرات أسيتات الصوديوم ، تريهالوز ثنائي الهيدرات، وماء للحقن، USP</p><p dir="RTL">(دستور الادوية الأمريكي).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يبدو سكاي ريزي ومحتويات العبوة</strong><br />يتوفر سكاي ريزي (ريسانكيزوماب) محلول للتسريب بتركيز ٦٠٠ ملغ / ١٠ مل في قنينة زجاجة وحيدة الجرعة تحتوي على محلول معقم وخالي من المواد الحافظة، عديم اللون أو مصفرّ، وشفاف إلى غميم قليلا ّ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كل قنينة زجاجية وحيدة الجرعة مغلقة بسدادة وغطاء قالب أزرق اللون.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجهة المسؤولة عن التصنيع:</strong></p><p dir="RTL">باثيون إيطاليا إس.بي.آي.،فيالي جان باتيستا ستوكي 110،مونزا، 20900، إيطاليا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p><strong>ا</strong><strong>لشركة المالكة لحق التسويق:</strong></p><p dir="RTL">آبفي إنك.، 1 ان طريق وكيجان</p><p dir="RTL">نورث شيكاغو، آي إل ٦٠٠٦٤،</p><p dir="RTL">الولايات المتحدة الأمريكية&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المسؤولة عن </strong><strong>إصدار التشغيلة</strong><strong>:</strong></p><p dir="RTL">آبفي إس.آر.إل.</p><p dir="RTL">اس.ار.148 بونتينا، 52 كم اس ان سي</p><p dir="RTL">04011 كمبوفيردي دي ابريليا (لاتينا)</p><p>إيطاليا<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	لقد تم مراجعة هذه النشرة لأخر مرة في يونيو ٢٠٢٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Skyrizi 600 mg solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SKYRIZI) (risankizumab) 600 mg/10 mL (60 mg/mL) solution for infusion is a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution for intravenous infusion. 
Each vial contains 10 mL.
Risankizumab, an interleukin-23 (IL-23) antagonist, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. Risankizumab is produced by recombinant DNA technology in Chinese hamster ovary cells and has an approximate molecular weight of 149 kDa. 

Excipients with known effect

This medicinal product contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium free’.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                solution for infusion (infusion)
the solution is colorless to slightly yellow, and clear to slightly opalescent solution in each single-dose vial. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Crohn&rsquo;s Disease </strong></p><p>SKYRIZI is indicated for the treatment of moderately to severely active Crohn&#39;s disease in adults.</p><p><strong>&nbsp;</strong></p><p><strong>Ulcerative Colitis</strong></p><p>SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Recommended Dosage for Crohn&rsquo;s Disease</strong></p><p><u>Adult Patients: Induction</u></p><p>The recommended induction dosage of SKYRIZI is 600 mg administered by intravenous infusion over a period of at least one hour at Week 0, Week 4, and Week 8.</p><p><u>&nbsp;</u></p><p><u>Adult Patients: Maintenance</u></p><p>The recommended maintenance dosage of SKYRIZI is 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter.</p><p>&nbsp;</p><p><strong>Recommended Dosage for Ulcerative Colitis</strong></p><p><u>&nbsp;</u></p><p><u>Adult Patients: Induction</u></p><p>The recommended induction dosage of SKYRIZI is 1,200 mg administered by intravenous infusion over a period of at least two hours at Week 0, Week 4, and Week 8.</p><p><u>&nbsp;</u></p><p><u>Adult Patients: Maintenance</u></p><p>The recommended maintenance dosage of SKYRIZI is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage needed to maintain therapeutic response.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Missed dose</u></p><p><em>&nbsp;</em></p><p>If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><strong>&nbsp;</strong></p><p><em>Geriatric Use</em></p><p>&nbsp;</p><p>Of the 6,862 subjects exposed to SKYRIZI, a total of 664 were 65 years or older (243 subjects with plaque psoriasis, 246 subjects with psoriatic arthritis, 72 subjects with Crohn&rsquo;s disease and 103 subjects with ulcerative colitis), and 71 subjects were 75 years or older.</p><p>Clinical studies of SKYRIZI, within each indication, did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.</p><p>No clinically meaningful differences in the pharmacokinetics of risankizumab were observed based on age.</p><p>&nbsp;</p><p><em>Renal or hepatic impairment</em></p><p><em>&nbsp;</em></p><p>No studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>The safety and effectiveness of SKYRIZI have not been established in pediatric patients.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>SKYRIZI vial for intravenous administration is intended for administration by a healthcare provider using aseptic technique. &nbsp;Please refer to section &ldquo;<em>6.6 Special precautions for disposal and other handling&rdquo; </em>for the proper injection technique.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Procedures Prior to Treatment Initiation </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the treatment of Crohn&rsquo;s disease and ulcerative colitis, obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI <em>[see Special warnings and precautions for use (</em><em>4.4</em><em>)]</em></p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI <em>[</em><em> see Special warnings and precautions for use</em><em> (</em><em>4.4</em><em>)]</em>.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete all age-appropriate vaccinations as recommended by current immunization guidelines <em>[</em><em> see Special warnings and precautions for use</em><em> (</em><em>4.4</em><em>)].</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab or any of the excipients [see Warnings and Precautions (4.4)]. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypersensitivity Reactions </strong></p><p>Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately <em>[see Adverse Reactions (</em><em>4.8</em><em>)]</em>.</p><p><strong>&nbsp;</strong></p><p><strong>Infections</strong></p><p>SKYRIZI may increase the risk of infections <em>[see Adverse Reactions (4.8)]</em>.</p><p>Treatment with SKYRIZI should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.</p><p>In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer SKYRIZI until the infection resolves.</p><p>&nbsp;</p><p><strong>Tuberculosis</strong></p><p>Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI. Across the Phase 3 psoriasis clinical studies, of the 72 subjects with latent TB who were concurrently treated with SKYRIZI 150 mg and appropriate TB prophylaxis during the studies, none developed active TB during the mean follow-up of 61 weeks on SKYRIZI. Two subjects taking isoniazid for treatment of latent TB discontinued treatment due to liver injury. Of the 31 subjects from the PsO-3 study with latent TB who did not receive prophylaxis during the study, none developed active TB during the mean follow-up of 55 weeks on SKYRIZI. Consider anti-TB therapy prior to initiating SKYRIZI in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Administration of Vaccines</strong></p><p>Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating therapy with SKYRIZI, complete all age-appropriate vaccinations according to current immunization guidelines. No data are available on the response to live or inactive vaccines.</p><p>&nbsp;</p><p><strong>Hepatotoxicity in Treatment of Inflammatory Bowel Disease</strong></p><p>A serious adverse reaction of drug-induced liver injury was reported in a patient with Crohn&rsquo;s disease (ALT 54x ULN, AST 30x ULN, and total bilirubin 2.2x ULN) following two intravenous doses of SKYRIZI 600 mg in conjunction with a rash that required hospitalization. The liver test abnormalities resolved following administration of steroids. SKYRIZI was subsequently discontinued.</p><p>For the treatment of Crohn&rsquo;s disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline, and during induction at least up to 12 weeks of treatment. Monitor thereafter according to routine patient management.</p><p>Consider other treatment options in patients with evidence of liver cirrhosis. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Cytochrome P450 Substrates</em></p><p>No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate), or midazolam (CYP3A substrate) were observed when used concomitantly with risankizumab in subjects with Crohn&rsquo;s disease or ulcerative colitis (risankizumab 1,800 mg administered intravenously at Weeks 0, 4 and 8, i.e., 3 times and 1.5 times the dose for Crohn&rsquo;s disease and ulcerative colitis, respectively).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p><u>Risk Summary</u></p><p>Available pharmacovigilance and clinical trial data with risankizumab use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Although there are no data on risankizumab, monoclonal antibodies can be actively transported across the placenta, and SKYRIZI may cause immunosuppression in the in utero<em>-</em>exposed infant<strong>.</strong> There are adverse pregnancy outcomes in women with inflammatory bowel disease <em>(see Clinical Considerations)</em>.</p><p>&nbsp;</p><p>In an enhanced pre- and post-natal developmental toxicity study, pregnant cynomolgus monkeys were administered subcutaneous doses of 5 or 50 mg/kg risankizumab once weekly during the period of organogenesis up to parturition. Increased fetal/infant loss was noted in pregnant monkeys at the 50 mg/kg dose <em>(see Data)</em>. The 50 mg/kg dose in pregnant monkeys resulted in approximately 5 times the exposure (AUC) in humans administered the maximum recommended induction dose (1,200 mg) and 32 times the exposure (AUC) to the maximum recommended maintenance dose (360 mg). No risankizumab related effects on functional or immunological development were observed in infant monkeys from birth through 6 months of age. The clinical significance of these findings for humans is unknown.</p><p>&nbsp;</p><p>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p>&nbsp;</p><p>Clinical Considerations</p><p><em>Disease-associated maternal and embryo/fetal risk</em></p><p>Published data suggest that the risk of adverse pregnancy outcomes in women with inflammatory bowel disease is associated with increased disease activity. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth.</p><p>&nbsp;</p><p><em>Fetal/Neonatal adverse reactions</em></p><p>Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses, and peaks during the third trimester. Because risankizumab may interfere with immune response to infections, risks and benefits should be considered prior to administering live vaccines to infants exposed to SKYRIZI in utero. There are insufficient data regarding infant serum levels of risankizumab at birth and the duration of persistence of risankizumab in infant serum after birth. Although a specific timeframe to delay live virus immunizations in infants exposed in utero is unknown, a minimum of 5 months after birth should be considered because of the half-life of the product.</p><p>.</p><p><u>Data</u></p><p><em>Animal Data</em></p><p>An enhanced pre- and post-natal developmental toxicity study was conducted in cynomolgus monkeys. Pregnant cynomolgus monkeys were administered weekly subcutaneous doses of risankizumab of 5 or 50 mg/kg from gestation day 20 to parturition, and the cynomolgus monkeys (mother and infants) were monitored for 6 months after delivery. No maternal toxicity was noted in this study. There were no treatment-related effects on growth and development, malformations, developmental immunotoxicology, or neurobehavioral development. However, a dose-dependent increase in fetal/infant loss was noted in the risankizumab -treated groups (32% and 43% in the 5 mg/kg and 50 mg/kg groups, respectively) compared with the vehicle control group (19%). The increased fetal/infant loss in the 50 mg/kg group was considered to be related to risankizumab treatment. The no observed adverse effect level (NOAEL) for maternal toxicity was identified as 50 mg/kg and the NOAEL for developmental toxicity was identified as 5 mg/kg. The 5 mg/kg dose in pregnant monkeys resulted in approximately 0.6 times the exposure (AUC) in humans administered the maximum recommended induction dose (1,200 mg) and 5 times the exposure (AUC) in humans administered the maximum recommended maintenance dose (360 mg). In the infants, mean serum concentrations increased in a dose-dependent manner and were approximately 17%-86% of the respective maternal concentrations. Following delivery, most adult female cynomolgus monkeys and all infants from the risankizumab -treated groups had measurable serum concentrations of risankizumab up to 91 days postpartum. Serum concentrations were below detectable levels at 180 days postpartum.</p><p><strong>Lactation</strong></p><p><u>Risk Summary</u></p><p>There are no data on the presence of risankizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Endogenous maternal IgG and monoclonal antibodies are transferred in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to Risankizumab are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother&#39;s clinical need for SKYRIZI and any potential adverse effects on the breastfed infant from SKYRIZI or from the underlying maternal condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Risankizumab has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The following adverse reactions are discussed in other sections of labeling [<em>see Special warnings and precautions for use (4.4)</em>]:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity Reactions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tuberculosis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatotoxicity in Treatment of Inflammatory Bowel Disease</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions for risankizumab from clinical studies (Table 1) are listed by MedDRA system organ class and are based on the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000); and very rare (&lt;&nbsp;1/10&nbsp;000).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 1: List of adverse reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Upper respiratory infections<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p><u>&nbsp;Urinary tract infection</u></p><p><sup>&nbsp;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Injection site reactions<sup>c*</sup></p><p>Pyrexia</p><p>Rash<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p><u>Abdominal pain<sup>e</sup></u></p></td></tr><tr><td style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Anemia</u></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Musculoskeletal and connective tissue disorders</u></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Arthralgia</u></p><p><u>Back pain</u></p><p><u>Arthropathy</u></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp; Includes: &nbsp;influenza like illness, nasopharyngitis, influenza, pharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, COVID-19, nasal congestion, respiratory tract infection viral, viral pharyngitis, tonsillitis, upper respiratory tract inflammation</p><p><sup>b</sup>&nbsp; Includes: headache, tension headache,</p><p><sup>c</sup> Includes: &nbsp;injection site rash, injection site erythema, injection site swelling, injection site urticaria, injection site warmth, injection site pain, injection site hypersensitivity, injection site reaction, application site pain, injection site pruritus</p><p><sup>d </sup>Includes: rash and rash macular</p><p><sup>e </sup>Includes: abdominal pain, abdominal pain upper, abdominal pain lower</p><p><strong>* </strong>Some subjects had multiple occurrences of injection site reactions. The adverse reaction is included only once per subject.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Clinical Trials Experience</u></p><p>Because clinical trials are conducted under widely varying conditions, adverse drug reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p><u>Crohn&rsquo;s Disease </u></p><p>SKYRIZI was studied up to 12 weeks in subjects with moderately to severely active Crohn&rsquo;s disease in two randomized, double-blind, placebo-controlled induction studies (CD-1, CD-2) and a randomized, double-blind, placebo-controlled, dose-finding study (CD-4; NCT02031276). Long-term safety up to 52 weeks was evaluated in subjects who responded to induction therapy in a randomized, double-blind, placebo-controlled maintenance study (CD-3).</p><p>In the two induction studies (CD-1, CD-2) and the dose finding study (CD-4), 620 subjects received the SKYRIZI intravenous induction regimen. In the maintenance study (CD-3), 142 subjects who achieved clinical response defined as a reduction in CDAI of at least 100 points from baseline after 12 weeks of induction treatment with intravenous SKYRIZI in studies CD-1 and CD-2, received SKYRIZI subcutaneously as a maintenance regimen.</p><p>Adverse reactions reported in &gt; 3% of subjects in induction studies and at a higher rate than placebo are shown in Table 2.</p><p>&nbsp;</p><p>Table 2. Adverse Drug Reactions Reported in &gt; 3% of Subjects with Crohn&rsquo;s Disease Treated with SKYRIZI in Placebo-Controlled 12-Week Induction Studies</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Adverse Drug Reactions</strong></p></td><td><p><strong>SKYRIZI</strong></p><p><strong>600 mg Intravenous Infusion<sup>a</sup><br />N = 620<br />n (%)</strong></p></td><td><p><strong>Placebo<br />N = 432<br />n (%)</strong></p></td></tr><tr><td><p>Upper respiratory infections<sup>b</sup></p></td><td><p>&nbsp; 66 (10.6)</p></td><td><p>40 (9.3)</p></td></tr><tr><td><p>Headache<sup>c</sup></p></td><td><p>41 (6.6)</p></td><td><p>24 (5.6)</p></td></tr><tr><td><p>Arthralgia</p></td><td><p>31 (5.0)</p></td><td><p>19 (4.4)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> SKYRIZI 600 mg as an intravenous infusion at Week 0, Week 4, and Week 8.</p><p><sup>b</sup> Includes: influenza like illness, nasopharyngitis, influenza, pharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, COVID-19, nasal congestion, respiratory tract infection viral, viral pharyngitis, tonsillitis, upper respiratory tract inflammation</p><p><sup>c</sup> Includes: headache, tension headache</p></td></tr></tbody></table><p>Adverse reactions reported in &gt;3% of subjects in the maintenance study and at a higher rate than placebo are shown in Table 3.</p><p><strong>Table 3. Adverse Reactions Reported in &gt;3% of Subjects with Crohn&rsquo;s Disease Treated with SKYRIZI in Placebo-Controlled 52-Week Maintenance Study (CD-3) </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Adverse Drug Reactions</strong></p></td><td><p><strong>SKYRIZI</strong></p><p><strong>360 mg Subcutaneous Injection<sup>a</sup><br />N = 142<br />n (%)</strong></p></td><td><p><strong>Placebo<br />N = 143<br />n (%)</strong></p></td></tr></thead><tbody><tr><td><p>Arthralgia</p></td><td><p>13 (9.2)</p></td><td><p>12 (8.4)</p></td></tr><tr><td><p>Injection site reactions<sup>b,c</sup></p></td><td><p>8 (5.6)</p></td><td><p>4 (2.8)</p></td></tr><tr><td><p>Abdominal pain<sup>d</sup></p></td><td><p>12 (8.5)</p></td><td><p>6 (4.2)</p></td></tr><tr><td><p>Anemia</p></td><td><p>7 (4.9)</p></td><td><p>6 (4.2)</p></td></tr><tr><td><p>Pyrexia</p></td><td><p>7 (4.9)</p></td><td><p>4 (2.8)</p></td></tr><tr><td><p>Back pain</p></td><td><p>6 (4.2)</p></td><td><p>3 (2.1)</p></td></tr><tr><td><p>Arthropathy</p></td><td><p>5 (3.5)</p></td><td><p>2 (1.4)</p></td></tr><tr><td><p>Urinary tract infection</p></td><td><p>5 (3.5)</p></td><td><p>4 (2.8)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> SKYRIZI 360 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks</p><p><sup>b</sup> Includes: injection site rash, injection site erythema, injection site swelling, injection site urticaria, injection site warmth, injection site pain, injection site hypersensitivity, injection site reaction</p><p><sup>c</sup> Some subjects had multiple occurrences of injection site reactions. The adverse reaction is included only once per subject.</p><p><sup>d</sup>Includes: abdominal pain, abdominal pain upper, abdominal pain lower</p></td></tr></tbody></table><p><u>Specific Adverse Drug Reactions</u></p><p><em>Infections</em></p><p>In the maintenance study (CD-3) through Week 52, the rate of infections was 36.6% (60.8 events per 100 subject-years) in subjects who received SKYRIZI compared to 36.4% (60.3 events per 100 subject-years) in subjects who received placebo after SKYRIZI induction. The rate of serious infections was 5.6% (7.4 events per 100 subject-years) in subjects who received SKYRIZI compared to 2.1% (2.4 events per 100 subject-years) in subjects who received placebo after SKYRIZI induction.</p><p><em>Lipid Elevations</em><br />&nbsp;</p><p>Elevations in lipid parameters (total cholesterol and low-density lipoprotein cholesterol [LDL-C]) were first assessed at 4 weeks following initiation of SKYRIZI in the induction trials (CD-1, CD-2). Increases from baseline and increases relative to placebo were observed at Week 4 and remained stable to Week 12. Following SKYRIZI induction, mean total cholesterol increased by 9.4 mg/dL from baseline to a mean absolute value of 175.1 mg/dL at Week 12. Similarly, mean LDL-C increased by 6.6 mg/dL from baseline to a mean absolute value of 92.6 mg/dL Week 12.</p><p>&nbsp;</p><p><u>Ulcerative Colitis </u></p><p>SKYRIZI was studied up to 12 weeks in subjects with moderately to severely active ulcerative colitis in a randomized, double-blind, placebo-controlled induction study (UC-1) and a randomized, double-blind, placebo-controlled, dose-finding study (UC-3). Long-term safety up to 52 weeks was evaluated in subjects who responded to induction therapy in a randomized, double-blind, placebo-controlled maintenance study (UC-2)<em>.</em></p><p><em>&nbsp;</em></p><p>In the induction studies (UC-1 and UC-3), 712 subjects received the SKYRIZI 1,200 mg intravenous induction regimen at Weeks 0, 4 and 8. In the maintenance study (UC-2), 347 subjects who achieved clinical response, defined as&nbsp; a decrease in mMS of &ge;2 points and &ge;30% from baseline and a decrease in RBS &ge;1 from baseline or an absolute RBS &le;1, received a maintenance regimen of SKYRIZI either 180 mg or 360 mg subcutaneously at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks.</p><p>&nbsp;</p><p>The adverse reaction reported in &ge;3% subjects treated with SKYRIZI in the ulcerative colitis induction studies (UC-1 and UC-3) and at a higher rate than placebo was arthralgia (3% SKYRIZI vs 1% placebo).</p><p>&nbsp;</p><p>Adverse reactions reported in &ge;3% of subjects treated with SKYRIZI in the maintenance study (UC-2) and at a higher rate than placebo are shown in Table 4.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table 4. Adverse Reactions Reported in &ge;3% of Subjects with Ulcerative Colitis Treated with SKYRIZI<sup>a</sup> in Placebo-Controlled 52-Week Maintenance Study (UC-2) </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Adverse Drug Reactions</strong></p></td><td style="vertical-align:top"><p><strong>SKYRIZI</strong></p><p><strong>180 mg Subcutaneous Injection<br />N = 170<br />n (%)</strong></p></td><td><p><strong>SKYRIZI</strong></p><p><strong>360 mg Subcutaneous Injection<br />N = 177<br />n (%)</strong></p></td><td><p><strong>Placebo<br />N = 173<br />n (%)</strong></p></td></tr></thead><tbody><tr><td><p>Arthralgia</p></td><td><p>9 (5.3)</p></td><td><p>17 (9.6)</p></td><td><p>8 (4.6)</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>8 (4.7)</p></td><td style="vertical-align:top"><p>7 (4.0)</p></td><td style="vertical-align:top"><p>6 (3.5)</p></td></tr><tr><td><p>Injection site reactions<sup>b,c</sup></p></td><td style="vertical-align:top"><p>5 (2.9)</p></td><td><p>&nbsp; 5 (2.8)</p></td><td><p>&nbsp;2 (1.2)</p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>d</sup></p></td><td style="vertical-align:top"><p>7 (4.1)</p></td><td style="vertical-align:top"><p>&nbsp;1 (0.6)</p></td><td style="vertical-align:top"><p>&nbsp; 3 (1.7)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup> SKYRIZI 180 mg or 360 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks</p><p><sup>b </sup>Includes: application site pain, injection site erythema, injection site pain, injection site pruritus, injection site reaction</p><p><sup>c </sup>Some subjects had multiple occurrences of injection site reactions. In this table, injection site reactions are counted only once per subject for the rate calculations.</p><p><sup>d</sup> Includes:<sup> </sup>rash and rash macular</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Specific Adverse Drug Reactions</u></p><p>The rates of infections, serious infections, and lipid elevations in subjects with UC who received SKYRIZI compared to subjects who received placebo in the induction studies (UC-1 and UC-3) and maintenance study (UC-2) were similar to the rates in subjects with CD who received SKYRIZI compared to subjects who received placebo in the induction studies (CD-1, CD-2, and CD-4) and maintenance study (CD-3).</p><p>&nbsp;</p><p>Immunogenicity</p><p>As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other products, including other risankizumab products, may be misleading.</p><p><u>&nbsp;</u></p><p><u>Crohn&rsquo;s Disease</u></p><p>&nbsp;</p><p>&nbsp;</p><p>By Week 64, approximately 3.4% (2/58) of subjects treated with SKYRIZI at the recommended induction and maintenance dosages developed antibodies to risankizumab. None of the subjects who developed antibodies to risankizumab had antibodies that were classified as neutralizing.</p><p>&nbsp;</p><p><u>Ulcerative Colitis</u></p><p>By Week 64, antibodies to risankizumab developed in approximately 8.9% (8/90) or 4.4% (4/91) of subjects treated with SKYRIZI induction followed by the 180 mg or 360 mg maintenance regimen, respectively. Of the subjects who developed antibodies to risankizumab, 75% (6.7% of all subjects treated with SKYRIZI induction followed by the 180 mg maintenance regimen) or 50% (2.2% of all subjects treated with SKYRIZI induction followed by the 360 mg maintenance regimen), respectively, had antibodies that were classified as neutralizing.</p><p><u>&nbsp;</u></p><p>&nbsp;</p><p><strong>Postmarketing Experience</strong></p><p>The following adverse reactions have been reported during post-approval of SKYRIZI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SKYRIZI exposure:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and subcutaneous tissue disorders: eczema and rash</p><p><em>&nbsp;</em></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via The The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC18</p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>risankizumab is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.</p><p>risankizumab inhibits the release of pro-inflammatory cytokines and chemokines.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>No formal pharmacodynamics studies have been conducted with risankizumab.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p><strong>&nbsp;</strong></p><p><u>Induction Trials (Studies CD-1 and CD-2)</u></p><p>In two 12-week induction studies (CD-1; NCT03105128 and CD-2; NCT03104413), subjects with moderately to severely active Crohn&rsquo;s disease were randomized to receive SKYRIZI 600 mg, SKYRIZI 1,200 mg, or placebo as an intravenous infusion at Week 0, Week 4, and Week 8. Moderately to severely active CD was defined as a Crohn&rsquo;s Disease Activity Index (CDAI) of 220 to 450 and Simple Endoscopic Score for Crohn&rsquo;s disease (SES-CD) &ge;6 (or &ge;4 for isolated ileal disease). Subjects with inadequate response, loss of response, or intolerance to oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic therapy were enrolled.&nbsp;</p><p>At baseline, the median CDAI was 307 (range: 76 &ndash; 634) and 307 (range: 72 &ndash; 651), and the median SES-CD was 12 (range: 4 &ndash; 45) and 13 (range 4 &ndash; 40), in CD-1 and CD-2, respectively. In CD-1, 58% (491/850) of subjects had failed or were intolerant to treatment with one or more biologic therapies (prior biologic failure). All subjects in CD-2 had prior biologic failure. At baseline, 30% and 34% of patients were receiving corticosteroids, 24% and 23% of patients were receiving immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), and 31% and 19% of patients were receiving aminosalicylates in CD-1 and CD-2, respectively. In CD-1 and CD-2 combined, the median age was 36 years (ranging from 16 to 80 years), 81% (1145/1419) of subjects were white, and 53% (753/1419) were male.</p><p>In CD-1 and CD-2, the co-primary endpoints were clinical remission and endoscopic response at Week 12. Secondary endpoints included clinical response and endoscopic remission (see Table 5 and Table 6). The SKYRIZI 1,200 mg dosage did not demonstrate additional treatment benefit over the 600 mg dosage and is not a recommended regimen <em>[see Dosage and Administration ]</em>.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>Table 5. Proportion of Subjects Meeting Efficacy Endpoints at Week 12 &ndash; Study CD-1</p><table border="0" cellspacing="0" cellpadding="0" style="width:615px"><tbody><tr><td><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>SKYRIZI</strong></p><p><strong>600 mg Intravenous Infusion<sup>a</sup></strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Treatment</strong></p><p><strong>Difference<sup> b</sup></strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td colspan="4"><p><strong>Clinical Remission<sup>c,d</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total Population</p></td><td><p>N=175</p><p>25%</p></td><td><p>N=336</p><p>45%</p></td><td style="vertical-align:top"><p><strong>21% <sup>e</sup></strong></p><p><strong>(12%, 29%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>f</sup></p></td><td><p>N=97</p><p>26%</p></td><td><p>N=195</p><p>42%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Without prior biologic failure</p></td><td><p>N=78</p><p>23%</p><p>&nbsp;</p></td><td><p>N=141</p><p>49%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Endoscopic Response<sup>c,g</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total Population</p></td><td><p>N=175</p><p>12%</p></td><td><p>N=336</p><p>40%</p></td><td style="vertical-align:top"><p><strong>28%<sup> e</sup></strong></p><p><strong>(21%, 35%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Prior biologic failure<sup>f</sup></p></td><td><p>N=97</p><p>11%</p></td><td><p>N=195</p><p>33%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Without prior biologic failure</p></td><td><p>N=78</p><p>13%</p></td><td><p>N=141</p><p>50%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Clinical Response<sup>h</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total Population</p></td><td><p>N=175</p><p>37%</p></td><td><p>N=336</p><p>60%</p></td><td style="vertical-align:top"><p><strong>23%<sup> e</sup></strong></p><p><strong>(14%, 32%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Prior biologic failure<sup>f</sup></p></td><td><p>N=97</p><p>34%</p></td><td><p>N=195</p><p>58%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Without prior biologic failure</p></td><td><p>N=78</p><p>40%</p></td><td><p>N=141</p><p>62%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Endoscopic Remission<sup>i</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total Population</p></td><td><p>N=175</p><p>9%</p></td><td><p>N=336</p><p>24%</p></td><td style="vertical-align:top"><p><strong>15%<sup> e</sup></strong></p><p><strong>(9%, 21%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Prior biologic failure<sup>f</sup></p></td><td><p>N=97</p><p>5%</p></td><td><p>N=195</p><p>18%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Without prior biologic failure</p></td><td><p>N=78</p><p>14%</p></td><td><p>N=141</p><p>32%</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a. SKYRIZI 600 mg as an intravenous infusion at Week 0, Week 4, and Week 8</p><p>b. Adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for randomization stratification factors</p><p>c. Co-primary endpoints</p><p>d. CDAI &lt;150</p><p>e. p &lt;0.001</p><p>f. Prior biologic failure includes inadequate response, loss of response, or intolerance to one or more biologic treatments for CD</p><p>g. A decrease in SES-CD &gt; 50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading</p><p>h. A reduction of CDAI &ge; 100 points from baseline</p><p>i. SES-CD &le; 4 and at least a 2-point reduction from baseline, with no individual subscore greater than 1, based on central reading</p></td></tr></tbody></table><p>&nbsp;</p><p>Table 6. Proportion of Subjects Meeting Efficacy Endpoints at Week 12 &ndash; Study CD-2<sup>a</sup></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p><p>N=187</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>SKYRIZI</strong></p><p><strong>600 mg Intravenous Infusion<sup>b</sup></strong></p><p>N=191</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Treatment</strong></p><p><strong>Difference<sup>c</sup></strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical Remission<sup>d,e</sup></strong></p></td><td><p>20%</p></td><td><p>42%</p></td><td><p>22%<sup> f</sup></p><p>(13%, 31%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endoscopic Response<sup> d,g</sup></strong></p></td><td><p>11%</p></td><td><p>29%</p></td><td><p>18%<sup> f</sup></p><p>(10%, 25%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical Response<sup>h</sup></strong></p></td><td><p>30%</p></td><td><p>60%</p></td><td><p>29%<sup> f</sup></p><p>(20%, 39%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endoscopic Remission<sup>i</sup></strong></p></td><td><p>4%</p></td><td><p>19%</p></td><td><p>15%<sup> f</sup></p><p>(9%, 21%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a. All subjects enrolled in CD-2 had prior biologic failure. Prior biologic failure includes inadequate response, loss of response, or intolerance to one or more biologic treatments for CD</p><p>b. SKYRIZI 600 mg as an intravenous infusion at Week 0, Week 4, and Week 8</p><p>c. Adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for randomization stratification factors</p><p>d. Co-primary endpoints</p><p>e. CDAI score &lt;150</p><p>f. p &lt; 0.001</p><p>g. A decrease in SES-CD &gt; 50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading</p><p>h. A reduction of CDAI &ge; 100 points from baseline</p><p>i. SES-CD &le; 4 and at least a 2-point reduction versus from baseline, with and no individual subscore greater than 1, based on central reading</p></td></tr></tbody></table><p>Onset of clinical response and clinical remission based on CDAI occurred as early as Week 4 in a greater proportion of subjects treated with the SKYRIZI 600 mg induction regimen compared to placebo.</p><p>&nbsp;</p><p>Reductions in stool frequency and abdominal pain were observed in a greater proportion of subjects treated with the SKYRIZI 600 mg induction regimen compared to placebo at Week 12.</p><p>&nbsp;</p><p><u>Study CD-3</u></p><p>The maintenance study CD-3 evaluated 247 subjects who achieved clinical response defined as a reduction in CDAI of at least 100 points from baseline after 12 weeks of induction treatment with intravenous SKYRIZI in studies CD-1 and CD-2. Subjects were randomized to receive a maintenance regimen of SKYRIZI 360 mg or placebo at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks.</p><p>The co-primary endpoints in CD-3 were clinical remission and endoscopic response at Week 52 (see Table 7).&nbsp;</p><p>&nbsp;<strong>Table 7.</strong> <strong>Proportion of Subjects Meeting Efficacy Endpoints at Week 52 - Study CD-3</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo<sup>a</sup></strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>SKYRIZI </strong></p><p><strong>360 mg Subcutaneous Injection<sup>b</sup></strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;Treatment Difference<sup> </sup>vs Placebo<sup>c</sup> </strong></p><p><strong>(95% CI</strong><strong>)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Clinical Remission<sup>d,e</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total Population</p></td><td><p>N=130</p><p>46%</p></td><td style="vertical-align:top"><p>N=117</p><p>57%</p></td><td style="vertical-align:top"><p>14%<sup> f</sup></p><p>(3%, 26%)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>g</sup></p></td><td><p>N=99</p><p>40%</p></td><td><p>N=83</p><p>51%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Without prior biologic failure</p></td><td><p>N=31</p><p>65%</p></td><td><p>N=34</p><p>71%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Endoscopic Response<sup>d,h</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total Population</p></td><td><p>N=130</p><p>22%</p></td><td style="vertical-align:top"><p>N=117</p><p>48%</p></td><td style="vertical-align:top"><p>31%<sup> f</sup></p><p>(21%, 41%)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>g</sup></p></td><td><p>N=99</p><p>21%</p></td><td><p>N=83</p><p>44%</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Without prior biologic failure</p></td><td><p>N=31</p><p>23%</p></td><td><p>N=34</p><p>59%</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>a. The placebo group consisted of patients who were in response to SKYRIZI and were randomized to receive placebo at the start of maintenance therapy.</p><p>b. SKYRIZI 360 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks</p><p>c. Adjusted treatment difference and 95% CI computed using Cochran-Mantel-Haenszel method adjusted for randomization stratification factors</p><p>d. Co-primary endpoints</p><p>e. CDAI &lt;150</p><p>f. p &lt;0.05</p><p>g. Prior biologic failure includes inadequate response, loss of response, or intolerance to one or more biologic treatments for CD</p><p>h. A decrease in SES-CD &gt; 50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading</p></td></tr></tbody></table><p>Endoscopic remission was observed at Week 52 in 41% (48/117) of subjects treated with the SKYRIZI maintenance regimen and 13% (17/130) of subjects treated with placebo. This endpoint was not statistically significant under the prespecified multiple testing procedure.</p><p><strong>&nbsp;</strong></p><p><strong>Ulcerative Colitis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><u>Induction Trial (Study UC-1)</u></p><p>In the 12-week induction study (UC-1; NCT03398148), 966 subjects with moderately to severely active ulcerative colitis were randomized and received SKYRIZI 1,200 mg or placebo as an intravenous infusion at Week 0, Week 4, and Week 8. Disease activity was assessed by the modified Mayo score (mMS), a 3-component Mayo score (0-9) which consists of the following subscores (0 to 3 for each subscore): stool frequency (SFS), rectal bleeding (RBS), and findings on centrally read endoscopy score (ES). An ES of 2 was defined by marked erythema, lack of vascular pattern, any friability, and/or erosions; an ES of 3 was defined by spontaneous bleeding and ulceration. Enrolled subjects had a mMS between 5 and 9, with an ES of 2 or 3. Subjects with inadequate response, or intolerance to oral aminosalicylates, corticosteroids, immunomodulators, biologics, Janus Kinase inhibitors (JAKi), and/or sphingosine-1-phosphate receptor modulators (S1PRM) were enrolled.&nbsp;</p><p>At baseline in UC-1, the median mMS was 7; 37% had severely active disease (mMS &gt;7); 69% had an ES of 3. In UC-1, 52% (499/966) of subjects had failed (inadequate response or intolerance) treatment with one or more biologics, JAKi or S1PRM. Of these 499 subjects, 484 (97%) failed biologics and 90 (18%) failed JAK inhibitors. &nbsp;Enrolled subjects were permitted to use a stable dose of oral corticosteroids (up to 20 mg/day prednisone or equivalent), immunomodulators, and aminosalicylates. At baseline, 36% of subjects were receiving corticosteroids, 16% of subjects were receiving immunomodulators (including azathioprine, 6-mercaptopurine, methotrexate), and 73% of subjects were receiving aminosalicylates in UC-1.</p><p>In UC-1, the primary endpoint was clinical remission defined using the mMS at Week 12 (see Table 8). Key secondary endpoints included clinical response, endoscopic improvement, and histologic endoscopic mucosal improvement (see Table 8).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Table 8. Proportion of Subjects Meeting Efficacy Endpoints at Week 12 &ndash; Study UC-1</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>SKYRIZI 1,200 mg Intravenous Infusion<sup>a</sup></strong></p></td><td><p><strong>Treatment Difference (95% CI)<sup>b</sup></strong></p></td></tr><tr><td colspan="4"><p><strong>Clinical Remission<sup>c</sup></strong></p></td></tr><tr><td><p>Total Population</p></td><td><p>N=320</p><p>8%</p></td><td><p>N=646</p><p>24%</p></td><td><p>16%<sup>h</sup></p><p>(12%, 20%)</p></td></tr><tr><td><p>Prior biologic, JAKi, or S1PRM failure<sup>d</sup></p></td><td><p>N=168</p><p>6%</p></td><td><p>N=331</p><p>14%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Without prior biologic, JAKi, or S1PRM failure</p></td><td><p>N=152</p><p>9%</p></td><td><p>N=315</p><p>33%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Clinical Response<sup>e</sup></strong></p></td></tr><tr><td><p>Total Population</p></td><td><p>N=320</p><p>36%</p></td><td><p>N=646</p><p>65%</p></td><td><p>29%<sup>h</sup></p><p>(23%, 35%)</p></td></tr><tr><td><p>Prior biologic, JAKi, or S1PRM failure<sup>d</sup></p></td><td><p>N=168</p><p>32%</p></td><td><p>N=331</p><p>56%</p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Without prior biologic, JAKi, or S1PRM failure</p></td><td><p>N=152</p><p>41%</p></td><td><p>N=315</p><p>75%</p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Endoscopic Improvement<sup>f</sup></strong></p></td></tr><tr><td><p>Total Population</p></td><td><p>N=320</p><p>12%</p></td><td><p>N=646</p><p>36%</p></td><td><p>25%<sup>h</sup></p><p>(20%, 30%)</p></td></tr><tr><td><p>Prior biologic, JAKi, or S1PRM failure<sup>d</sup></p></td><td><p>N=168</p><p>10%</p></td><td><p>N=331</p><p>26%</p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Without prior biologic, JAKi, or S1PRM failure</p></td><td><p>N=152</p><p>14%</p></td><td><p>N=315</p><p>47%</p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Histologic Endoscopic Mucosal Improvement (HEMI)<sup>g</sup></strong></p></td></tr><tr><td><p>Total Population</p></td><td><p>N=320</p><p>7%</p></td><td><p>N=646</p><p>24%</p></td><td><p>17%<sup>h</sup></p><p>(13%, 21%)</p></td></tr><tr><td><p>Prior biologic, JAKi, or S1PRM failure<sup>d</sup></p></td><td><p>N=168</p><p>7%</p></td><td><p>N=331</p><p>16%</p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Without prior biologic, JAKi, or S1PRM failure</p></td><td><p>N=152</p><p>8%</p></td><td><p>N=315</p><p>33%</p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup> SKYRIZI 1,200 mg as an intravenous infusion at Week 0, Week 4, and Week 8</p><p><sup>b </sup>Adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for stratification factors</p><p><sup>c</sup> Per mMS:&nbsp; SFS &le; 1 and not greater than baseline, RBS = 0, and ES &le; 1 without friability</p><p><sup>d</sup> Prior failure includes inadequate response or intolerance to treatment with one or more of the following: biologic therapies, Janus Kinase inhibitors (JAKi), and/or sphingosine-1-phosphate receptor modulators (S1PRM)</p><p><sup>e</sup> Per mMS: decrease &ge; 2 points and &ge; 30% from baseline, and a decrease in RBS &ge; 1 from baseline or an absolute RBS &le; 1</p><p><sup>f</sup> ES &le; 1 without the evidence of friability</p><p><sup>g</sup> ES <strong>&le;</strong> 1 without the evidence of friability and Geboes score &le; 3.1 (indicating neutrophil infiltration in &lt;5% of crypts, no crypt destruction and no erosions, ulcerations or granulation tissue)</p><p><sup>h</sup> p &lt; 0.001</p></td></tr></tbody></table><p>UC-1 was not designed to evaluate the relationship of histologic endoscopic mucosal improvement at week 12 to disease progression and long-term outcomes.</p><p><em>&nbsp;</em></p><p><em>Rectal Bleeding and Stool Frequency Subscores</em></p><p>&nbsp;</p><p>Decreases in rectal bleeding and stool frequency subscores in subjects treated with SKYRIZI compared to placebo were observed as early as 4 weeks.</p><p><em>Endoscopic Assessment </em></p><p>Endoscopic remission was defined as ES of 0. At Week 12, a greater proportion of subjects treated with SKYRIZI compared to placebo achieved endoscopic remission (11% vs 3%).</p><p><em>Bowel Urgency</em></p><p>A greater proportion of subjects treated with the SKYRIZI 1,200 mg induction regimen compared to placebo had no bowel urgency (44% vs 27%) at Week 12.</p><p><em>Fatigue</em></p><p>In UC-1, subjects treated with SKYRIZI experienced a clinically meaningful improvement in fatigue, assessed by change from baseline in FACIT-F score, at Week 12, compared to placebo-treated subjects. The effect of SKYRIZI to improve fatigue after 12 weeks of induction has not been established.</p><p><em>Other UC Symptoms </em></p><p>The proportion of subjects who had no nocturnal bowel movements was greater in subjects treated with SKYRIZI compared to placebo at Week 12 (67% vs 43%).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Maintenance Study UC-2</u></p><p>The maintenance study (UC-2; NCT03398135) evaluated 547 subjects who received one of three SKYRIZI induction regimens, including the 1,200 mg regimen, for 12 weeks in Studies UC-1 or UC-3 and demonstrated clinical response per mMS after 12 weeks. Subjects were randomized to receive a maintenance regimen of subcutaneous (SC) SKYRIZI 180 mg or SKYRIZI 360 mg or placebo at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks.</p><p>In UC-2, 75% (411/547) of subjects had failed (inadequate response or intolerance) treatment with one or more biologics, JAKi, or S1PRM. Of these 411 subjects, 407 (99%) failed biologics and 78 (19%) failed JAK inhibitors.</p><p>The primary endpoint in UC-2 was clinical remission using mMS at Week 52 (see Table 9). Key secondary endpoints included corticosteroid-free clinical remission, endoscopic improvement, and histologic endoscopic mucosal improvement (see Table 9).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 9.</strong> <strong>Proportion of Subjects Meeting Efficacy Endpoints at Week 52 - Study UC-2</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:642px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>SKYRIZI 180 mg SC Injection<sup>b</sup></strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>SKYRIZI 360 mg SC Injection<sup>c</sup></strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4"><p>Clinical remission<sup>d</sup></p></td></tr><tr><td><p>Total Population</p></td><td><p>N=182</p><p>26%</p></td><td><p>N=179</p><p>45%</p></td><td><p>N=186</p><p>41%</p></td></tr><tr><td><p>Treatment Difference vs Placebo<sup>e</sup> (95% CI)</p></td><td><p>&nbsp;</p></td><td><p>20%<sup> </sup><sup>j</sup></p><p>[11%, 29%]</p></td><td><p>16%<sup> j</sup></p><p>[7%, 25%]</p></td></tr><tr><td><p>Prior biologic, JAKi, or S1PRM failure<sup>f</sup></p></td><td><p>N=138</p><p>24%</p></td><td><p>N=134</p><p>41%</p></td><td><p>N=139</p><p>32%</p></td></tr><tr><td><p>Without prior biologic, JAKi, or S1PRM failure</p></td><td><p>N=44</p><p>32%</p></td><td><p>N=45</p><p>58%</p></td><td><p>N=47</p><p>67%</p></td></tr><tr><td colspan="4"><p>Corticosteroid-free clinical remission<sup>g</sup></p></td></tr><tr><td><p>Total Population</p></td><td><p>N=182</p><p>26%</p></td><td><p>N=179</p><p>45%</p></td><td><p>N=186</p><p>40%</p></td></tr><tr><td><p>Treatment Difference vs Placebo<sup>e</sup> (95% CI)</p></td><td><p>&nbsp;</p></td><td><p>20%<sup> j</sup></p><p>[11%, 29%]</p></td><td><p>16%<sup>j</sup></p><p>[7%, 25%]</p></td></tr><tr><td><p>&nbsp;Prior biologic, JAKi, or S1PRM failure<sup>f</sup></p></td><td><p>N=138</p><p>24%</p></td><td><p>N=134</p><p>40%</p></td><td><p>N=139</p><p>32%</p></td></tr><tr><td><p>Without prior biologic, JAKi, or S1PRM failure</p></td><td><p>N=44</p><p>32%</p></td><td><p>N=45</p><p>58%</p></td><td><p>N=47</p><p>64%</p></td></tr><tr><td colspan="4"><p>Endoscopic improvement<sup>h</sup></p></td></tr><tr><td><p>Total Population</p></td><td><p>N=182</p><p>31%</p></td><td><p>N=179</p><p>51%</p></td><td><p>N=186</p><p>48%</p></td></tr><tr><td><p>Treatment Difference vs Placebo<sup>e</sup> (95% CI)</p></td><td><p>&nbsp;</p></td><td><p>20%<sup> </sup><sup>j</sup></p><p>[11%, 30%]</p></td><td><p>18%<sup> </sup><sup>j</sup></p><p>[8%, 27%]</p></td></tr><tr><td><p>Prior biologic, JAKi, or S1PRM failure<sup>f</sup></p></td><td><p>N=138</p><p>30%</p></td><td><p>N=134</p><p>48%</p></td><td><p>N=139</p><p>39%</p></td></tr><tr><td><p>Without prior biologic, JAKi, or S1PRM failure</p></td><td><p>N=44</p><p>34%</p></td><td><p>N=45</p><p>60%</p></td><td><p>N=47</p><p>76%</p></td></tr><tr><td colspan="4"><p>Histologic Endoscopic Mucosal Improvement<sup>i</sup></p></td></tr><tr><td><p>Total Population</p></td><td><p>N=182</p><p>24%</p></td><td><p>N=179</p><p>43%</p></td><td><p>N=186</p><p>42%</p></td></tr><tr><td><p>Treatment Difference vs Placebo<sup>e</sup> (95% CI)</p></td><td><p>&nbsp;</p></td><td><p>20%<sup> j</sup></p><p>[11%, 29%]</p></td><td><p>20%<sup> j</sup></p><p>[11%, 29%]</p></td></tr><tr><td><p>Prior biologic, JAKi, or S1PRM failure<sup>f</sup></p></td><td><p>N=138</p><p>22%</p></td><td><p>N=134</p><p>39%</p></td><td><p>N=139</p><p>33%</p></td></tr><tr><td><p>Without prior biologic, JAKi, or S1PRM failure</p></td><td><p>N=44</p><p>30%</p></td><td><p>N=45</p><p>55%</p></td><td><p>N=47</p><p>69%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup> The placebo group consisted of subjects who were in response to 12 weeks of SKYRIZI induction and were randomized to receive placebo at the start of maintenance therapy.</p><p><sup>b</sup> SKYRIZI 180 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks</p><p><sup>c</sup> SKYRIZI 360 mg at Week 12 and every 8 weeks thereafter for up to an additional 52 weeks</p><p><sup>d</sup> Per mMS: SFS &le; 1 and not greater than baseline, RBS = 0, and ES &le; 1 without friability</p><p><sup>e</sup> Adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for stratification factors</p><p><sup>f</sup> Prior failure includes inadequate response or intolerance to treatment with one or more of the following: biologic therapies, Janus Kinase inhibitors (JAKi), and/or sphingosine-1-phosphate receptor modulators (S1PRM)</p><p><sup>g</sup> Clinical remission per mMS at Week 52 and corticosteroid-free for &ge;90 days</p><p><sup>h</sup> ES &le; 1 without the evidence of friability</p><p><sup>i</sup> ES &le; 1without the evidence of friability and Geboes score &le; 3.1 (indicating neutrophil infiltration in &lt;5% of crypts, no crypt destruction and no erosions, ulcerations or granulation tissue)</p><p><sup>j</sup> p &lt; 0.001</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Endoscopic Assessment </em></p><p>Endoscopic remission was defined as ES of 0. In UC-2, a greater proportion of subjects treated with SKYRIZI 180 mg and SKYRIZI 360 mg compared to placebo achieved endoscopic remission at Week 52 (23% and 24% vs 15%).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacokinetics</strong></p><p>Risankizumab plasma concentrations, after single dose administration increased dose proportionally from 18 mg to 360 mg when administered subcutaneously (0.1 to 2 times the lowest recommended dose and 0.05 to 1 times the highest recommended dose) and from 200 mg to 1,800 mg when administered as an up to 3-hour intravenous infusion (0.2 to 3 times the recommended dose) in healthy subject.</p><p><s>&nbsp;</s></p><p>In subjects with Crohn&rsquo;s disease treated with 600 mg IV induction dose at Weeks 0, 4, and 8 followed by 360 mg SubCutaneous maintenance dose at Week 12 and every 8 weeks thereafter, the median C<sub>max</sub> and C<sub>trough</sub> are estimated to be 156 and 38.8 mcg/mL respectively during the induction period (Weeks 8-12) and the median C<sub>max</sub> and C<sub>trough</sub> are estimated to be 28.0 and 8.13 mcg/mL respectively during the maintenance period (Weeks 40-48).</p><p><u>&nbsp;</u></p><p>In subjects with ulcerative colitis treated with 1,200 mg intravenous induction dose at Weeks 0, 4, and 8, followed by 180 mg or 360 mg subcutaneous maintenance dose at Week 12 and every 8 weeks thereafter, the median C<sub>max</sub> and C<sub>trough</sub> are estimated to be 350 and 87.7 mcg/mL, respectively, during the induction period (Weeks 8-12); and the steady state median C<sub>max&shy; </sub>and C<sub>trough</sub> are estimated to be 19.6 and 4.64 &micro;g/mL, respectively, for 180 mg or 39.2 mcg/mL and 9.29 mcg/mL, respectively, for 360 mg, during the maintenance period (Weeks 40-48).</p><p>Based on population pharmacokinetic analyses, the pharmacokinetics of risankizumab in subjects with ulcerative colitis was generally similar to that in subjects with Crohn&rsquo;s disease.</p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>The absolute bioavailability of risankizumab was estimated to be 74 to 89% following subcutaneous injection. In healthy subjects, following administration of a single subcutaneous dose, C<sub>max</sub> was reached by 3 to 14 days.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>The estimated steady-state volume of distribution (inter-subject CV%) was 7.68 L (64%) in subjects with Crohn&rsquo;s disease.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>The estimated systemic clearance (inter-subject CV%) was 0.31 L/day (24%) and 0.30 L/day (34%) and terminal elimination half-life was approximately 21 days in subjects with Crohn&rsquo;s disease,.</p><p><u>&nbsp;</u></p><p><u>Metabolism</u></p><p>The metabolic pathway of risankizumab has not been characterized. As a humanized IgG1 monoclonal antibody, risankizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.</p><p><u>&nbsp;</u></p><p><u>Specific Populations</u></p><p>Risankizumab exposures (C<sub>trough</sub>) in geriatric patients (&ge;65 years) are comparable to those in younger adult patients within each indication. No studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab.</p><p><em>&nbsp;</em></p><p><em>Body Weight</em></p><p>Risankizumab clearance and volume of distribution increase and plasma concentrations decrease as body weight increases; however, no dose adjustment is recommended based on body weight.</p><p><u>&nbsp;</u></p><p>&nbsp;</p><p><u>Drug Interaction Studies</u></p><p><em>&nbsp;</em></p><p><em>Cytochrome P450 Substrates</em></p><p>No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate), or midazolam (CYP3A substrate) were observed when used concomitantly with risankizumab in subjects with Crohn&rsquo;s disease or ulcerative colitis (risankizumab 1,800 mg administered intravenously at Weeks 0, 4, and 8, i.e., 3 times and 1.5 times the recommended dose for Crohn&rsquo;s disease and ulcerative colitis, respectively)..</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Nonclinical Toxicology</strong></p><p><strong><em>Carcinogenesis, Mutagenesis, Impairment of Fertility</em></strong></p><p>No effects on male fertility parameters were observed in sexually mature male cynomolgus monkeys dosed weekly for 26 weeks with 50 mg/kg risankizumab at 4 times the exposure (AUC) in humans administered the maximum recommended induction dose (1,200 mg) and 39 times the exposure in humans administered the maximum recommended maintenance dose (360 mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each SKYRIZI 600 mg/10 mL (60 mg/mL) solution for infusion vial contains:</p><p>Glacial Acetic acid (0.54 mg),</p><p>Polysorbate 20 (2 mg),</p><p>Sodium acetate(7.5 mg),</p><p>Trehalose(633.3 mg),</p><p>Water for Injection, USP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp;&nbsp;&nbsp; Store in a refrigerator at 2&deg;C to 8&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&bull;&nbsp;&nbsp;&nbsp; Do not shake.</p><p>&bull;&nbsp;&nbsp;&nbsp; Keep in the original cartons to protect from light.</p><p>&nbsp;</p><p><u>Storage of Diluted Solution: </u></p><p>Use the prepared infusion immediately. If not used immediately, store the diluted SKYRIZI solution refrigerated and protected from light for up to 20 hours between 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C).Immediately after preparation or removal from refrigerator, the diluted SKYRIZI solution can be stored at room temperature at up to 77&deg;F (25&deg;C) (protected from sunlight) for 4 hours (cumulative time from dilution to start of infusion). Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SKYRIZI (risankizumab) solution for infusion is supplied in sterile 600 mg/10 mL single-dose glass vial containing a sterile and preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution. Each single-dose glass vial is closed with a stopper and blue flip cap.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Intravenous Induction Dosing Regimen:</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; SKYRIZI vial for intravenous administration is intended for administration by a healthcare provider using aseptic technique.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Prior to intravenous administration, determine the dose and number of SKYRIZI vials needed based on the patient&rsquo;s indication (see table below). Withdraw 10 mL of SKYRIZI solution from a vial (600 mg/10 mL) and inject into an intravenous infusion bag or glass bottle containing 5% Dextrose Injection or 0.9% Sodium Chloride Injection (see Table 10 below) for a final concentration of approximately 1.2 mg/mL to 6 mg/mL. Discard any remaining solution in the vial.</p><p><br /><strong>Table 10. Total Volume of Diluent Required for Intravenous Induction Dose</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td><p><br /><strong>Indication</strong></p></td><td><p><strong>Intravenous Induction Dose</strong></p></td><td style="vertical-align:top"><p><strong>Number of SKYRIZI 600 mg/10 mL Vials</strong></p></td><td><p><strong>Total Volume of 5% Dextrose or </strong></p><p><strong>0.9% Sodium Chloride Injection</strong></p></td></tr><tr><td><p>Crohn&rsquo;s disease</p></td><td><p>600 mg</p></td><td style="vertical-align:top"><p>1</p></td><td><p>100 mL, or 250 mL, or 500 mL</p></td></tr><tr><td><p>Ulcerative colitis</p></td><td><p>1,200 mg</p></td><td style="vertical-align:top"><p>2</p></td><td><p>250 mL, or 500 mL<s> </s></p></td></tr></tbody></table><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Infuse the diluted solution intravenously over a period of at least one hour for the SKYRIZI 600 mg dose; at least two hours for the SKYRIZI 1,200 mg dose. The infusion should be completely administered&nbsp; within 4 hours after start of infusion. If stored refrigerated, allow the diluted SKYRIZI solution in the infusion bag or glass bottle to warm to room temperature prior to the start of the intravenous infusion.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Do not administer SKYRIZI diluted solution concomitantly in the same intravenous line with other medicinal products.</p><p><u>Handling and Storage of the Vial and the Diluted Solution:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake the vial or diluted solution in the infusion bag or glass bottle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use the prepared infusion immediately. If not used immediately, store the diluted SKYRIZI solution refrigerated and protected from light for up to 20 hours between 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediately after preparation or removal from refrigeration, the diluted SKYRIZI solution can be stored at room temperature at up to 77&deg;F (25&deg;C) (protected from sunlight) for 4 hours (cumulative time from start of dilution to start of infusion).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exposure to indoor light is acceptable during room temperature storage and administration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AbbVie Inc.
North Chicago, IL 60064, USA 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>